We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
These 3 Companies Reported Record Results and Raised Guidance
Key Takeaways
Despite many weak post-earnings reactions, overall Q2 earnings results have been positive.
JNJ, TSM, and ABT all posted strong numbers, with each breaking records and lifting guidance.
The 2026 Q2 earnings cycle continues to roll along, with the reporting docket remaining stacked in the coming days and weeks. The period has been another one of positivity so far, with several companies, including Abbott Laboratories (ABT - Free Report) , Taiwan Semiconductor (TSM - Free Report) , and Johnson & Johnson (JNJ - Free Report) all reporting record-breaking results in one way or another.
ABT Shares Bounce Back
Abbott Laboratories posted a double-beat relative to our consensus expectations while also lifting its adjusted EPS guidance. Sales of $12.6 billion reflected an all-time high for the company, growing by a double-digit 13% year-over-year.
Image Source: Zacks Investment Research
The stock has bounced back by 15% over the past month following a weak start in the first half of the year, with the recent set of quarterly results injecting positivity. The post-earnings reaction was the first one of positivity that we’ve seen in recent periods, with the recent earnings upgrade likely to keep momentum positive for the near-term.
Keep in mind that the stock also offers a nice dividend payout, with shares currently yielding 2.4% annually. Payouts have also grown consistently over its history, with ABT not only a Dividend Aristocrat but a Dividend King as well.
TSM Shares Face Volatility
Taiwan Semiconductor, a current Zacks Rank #2 (Buy), has been caught up in the recent weakness we’ve seen among many leading AI-related names, down 14% over the last month overall. It manufactures the powerful chips needed to run next-generation AI technologies.
Sales of $40.2 billion in its recent release grew 33% YoY and reflected a new record, with the company also raising its full-year revenue growth forecast to roughly 40%. TSM’s revenue has melted higher as of late, with the recent $40.2 billion in quarterly sales reported nearly doubling since 2024 Q2.
Image Source: Zacks Investment Research
JNJ Quietly Outperforms
Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up nearly 30%. The 3.2% gain over the last month has similarly shown nice outperformance relative to the S&P 500, with the recent results leading to positive momentum post-earnings.
Sales of $25.3 billion reflected a new quarterly record for the company, growing by a solid 6.6% year-over-year. It also increased both its current fiscal year sales and adjusted EPS guidance, with JNJ now on track to meet its 2026 target of more than $100 billion in annual revenue for the first time in its history.
Image Source: Zacks Investment Research
Bottom Line
The 2026 Q2 earnings season continues to roll along, and results have been positive for many companies, including Abbott Laboratories (ABT - Free Report) , Taiwan Semiconductor (TSM - Free Report) , and Johnson & Johnson (JNJ - Free Report) . Not all companies have seen great post-earnings reactions, but the overall earnings landscape remains one of strength.
The 2026 Q2 earnings season continues to roll along, and results have been positive for many companies, including Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson. Not all companies have seen great post-earnings reactions, but the overall earnings landscape remains one of strength.
View the Zacks #1 Rank List
Image: Bigstock
These 3 Companies Reported Record Results and Raised Guidance
Key Takeaways
The 2026 Q2 earnings cycle continues to roll along, with the reporting docket remaining stacked in the coming days and weeks. The period has been another one of positivity so far, with several companies, including Abbott Laboratories (ABT - Free Report) , Taiwan Semiconductor (TSM - Free Report) , and Johnson & Johnson (JNJ - Free Report) all reporting record-breaking results in one way or another.
ABT Shares Bounce Back
Abbott Laboratories posted a double-beat relative to our consensus expectations while also lifting its adjusted EPS guidance. Sales of $12.6 billion reflected an all-time high for the company, growing by a double-digit 13% year-over-year.
Image Source: Zacks Investment Research
The stock has bounced back by 15% over the past month following a weak start in the first half of the year, with the recent set of quarterly results injecting positivity. The post-earnings reaction was the first one of positivity that we’ve seen in recent periods, with the recent earnings upgrade likely to keep momentum positive for the near-term.
Keep in mind that the stock also offers a nice dividend payout, with shares currently yielding 2.4% annually. Payouts have also grown consistently over its history, with ABT not only a Dividend Aristocrat but a Dividend King as well.
TSM Shares Face Volatility
Taiwan Semiconductor, a current Zacks Rank #2 (Buy), has been caught up in the recent weakness we’ve seen among many leading AI-related names, down 14% over the last month overall. It manufactures the powerful chips needed to run next-generation AI technologies.
Sales of $40.2 billion in its recent release grew 33% YoY and reflected a new record, with the company also raising its full-year revenue growth forecast to roughly 40%. TSM’s revenue has melted higher as of late, with the recent $40.2 billion in quarterly sales reported nearly doubling since 2024 Q2.
Image Source: Zacks Investment Research
JNJ Quietly Outperforms
Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up nearly 30%. The 3.2% gain over the last month has similarly shown nice outperformance relative to the S&P 500, with the recent results leading to positive momentum post-earnings.
Sales of $25.3 billion reflected a new quarterly record for the company, growing by a solid 6.6% year-over-year. It also increased both its current fiscal year sales and adjusted EPS guidance, with JNJ now on track to meet its 2026 target of more than $100 billion in annual revenue for the first time in its history.
Image Source: Zacks Investment Research
Bottom Line
The 2026 Q2 earnings season continues to roll along, and results have been positive for many companies, including Abbott Laboratories (ABT - Free Report) , Taiwan Semiconductor (TSM - Free Report) , and Johnson & Johnson (JNJ - Free Report) . Not all companies have seen great post-earnings reactions, but the overall earnings landscape remains one of strength.
The 2026 Q2 earnings season continues to roll along, and results have been positive for many companies, including Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson. Not all companies have seen great post-earnings reactions, but the overall earnings landscape remains one of strength.